SOURCE: Medivation


September 23, 2011 16:00 ET

Medivation Announces Participation at Two Upcoming Investor Conferences

SAN FRANCISCO, CA--(Marketwire - Sep 23, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the following two investor conferences:

  • The JMP Securities Healthcare Conference on September 27 at 1:30pm Eastern Time at the St. Regis Hotel in New York City

  • The NewsMakers in the Biotech Industry Conference on October 21 at 9:30am Eastern Time at the Millennium Broadway Hotel in New York City

Dr. Hung will provide an overview of Medivation and its clinical development programs. A live audio webcast of each presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer and mild-to-moderate Alzheimer's disease. For more information, please visit us at

Contact Information

  • Contacts:
    Patrick Machado
    Chief Business & Financial Officer
    (415) 829-4101

    Anne Bowdidge
    Investor Relations
    (650) 218-6900